NewCardio to Demonstrate the Innovative CardioBip at the Heart Rhythm Society Annual Meeting

SANTA CLARA, Calif., May 7 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, will unveil its patented CardioBip™ technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society (HRS) 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

NewCardio will be at booth number 2147, giving conference attendees the opportunity to learn about NewCardio's unique 3-D platform technology:  CardioBip, a unique, hand-held device that provides an effective,  solution for ECG remote monitoring; Cardio3KG™, advanced software which provides quantitative analyses of cardiac electrical activity, with improved sensitivity and specificity over the standard 12-lead ECG for diagnosis of acute coronary events; and QTinno™ , a software solution that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety in drug development. In addition, NewCardio personnel will be on-hand to demonstrate the CardioBip, both at the Company's booth and on May 13th in a suite at the Hyatt Regency Denver, adjacent to the Denver Convention Ctr where HRS is held. Session attendees can utilize the CardioBip on themselves to see first-hand the simplicity and effectiveness of the technology.

HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders.  Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards.  The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at http://www.hrsonline.org/Sessions/ on the internet.

Images of NewCardio's CardioBip are available on the internet at http://www.newcardio.com/products-cardio-bip.php.

NewCardio's CEO, Branislav Vajdic, PhD., commented, "CardioBip is the first remote, wireless, non-invasive device which provides accurate 12-lead ECG results, and as such we believe it will propel remote cardiac monitoring to an entirely new level.  This is the culmination of several years of work to advance this technology, and we are excited to share this significant clinical and technological advancement with scientists, medical professionals and industry leaders at the HRS Annual Scientific Sessions.  With its 3-D technology, CardioBip will provide important data that addresses significant problems with the diagnosis and treatment of chronic cardiac conditions."

In addition, and as previously announced, the HRS has accepted an abstract  detailing the superior performance of NewCardio's CardioBip, particularly in patients with atrial fibrillation for its oral presentation.  The abstract, titled "Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation," was written by Alexei Shvilkin, MD, PhD, Dejan Vukajlovic, MD, Vladan Vukcevic, MD, Ihor Gussak, MD, PhD, Bosko Bojovic, PhD, Uros Mitrovic, MS and Goran Simic, MS.  The abstract discusses the use of CardioBip for improved atrial fibrillation (AF) monitoring and detection, highlighting a new AF detection algorithm based on NewCardio's proprietary 3-D ECG processing platform.

The CardioBip is a unique, hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop.  What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs.  The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.  The device is not currently approved for sale or distribution in the United States.  On January 12, 2010, the U.S. Patent and Trademark Office issued patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing."  This represents the core patent for CardioBip.  Additional patent applications covering the CardioBip have been submitted.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG.  NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect.  NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

SOURCE NewCardio, Inc.